IgA nephropathy (IgAN) is the leading primary cause of glomerular nephritis and a significant contributor to kidney failure, necessitating dialysis or transplantation. Join renowned experts, Drs. Jürgen Floege and Jonathan Barratt, as they discuss recent clinical trial outcomes and their impact on the continuously evolving IgAN treatment landscape.
Understanding the Recent Advances in IgAN
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Jürgen Floege, MD
Director
RWTH Aachen University Hospital
Aachen, GermanyDr. Floege has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, Bayer, Boehringer, Calliditas, Novartis, Omeros, Travere, Vifor
Other: Novo Nordisk, VisterraFaculty:
Jonathan Barratt, MD, PhD, FRCP
The Mayer Professor of Renal Medicine
University of Leicester
Leicester, United KingdomDr. Barratt has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: CalliditasReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Ann Early has nothing to disclose.
- Howard Green has nothing to disclose.
- Amanda Hilferty has nothing to disclose.
- Hany Ibrahim, MD, has nothing to disclose.
- Tim Person has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Compare and contrast the mechanisms of action of emerging therapeutic options for patients with immunoglobulin A nephropathy (IgAN)
- Evaluate the efficacy and safety profiles of emerging therapeutic options for patients with IgAN
- Interpret the clinical relevance of recent trial findings in patients with IgAN
Target Audience
This activity is designed to meet the educational needs of nephrologists and rheumatologists.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from CSL Vifor.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Kelly Chenlei Li, MBBS, FRACP
Paul Bennett, RN, MHSM, PhD, FISN
Thilo Krüger, MD, PhD
Jurgen Floege MD
Uyen Huynh-Do, MD
- CME/CE
Implementing a Successful Barostim Program in the Clinic: Best Practices and Real World Experience
Jessica Griffiths, PA-C
Anna L. Rourke, NP